ENGINEERED LIPOSOMES FOR NEUTRALIZATION OF SARS-COV-2 AND OTHER ENVELOPED VIRUSES

Smart overview of the Invention

Engineered nanoparticles, specifically liposomes, have been developed to inhibit enveloped viruses. These nanoparticles are designed to contain specific targeting molecules that interact with viral attachment proteins, providing a method for neutralizing viruses such as SARS-CoV-2. The liposomes can also carry reagents capable of damaging or destroying the viral genetic material upon delivery.

Importance of Antiviral Strategies

The emergence of various viral outbreaks, including the COVID-19 pandemic, highlights the urgent need for effective antiviral treatments. Currently, only a limited number of antiviral drugs are approved for use against human viral pathogens. The lack of treatment options for many viruses necessitates the development of broad-spectrum antiviral therapies to prepare for future outbreaks and protect public health.

Mechanism of Action

The proposed method involves administering nanoparticles that present surface-exposed cell receptor molecules, which mediate the entry of enveloped viruses into host cells. These receptors may include a variety of proteins such as ACE-2 and CD4. The interaction between the nanoparticles and the virus facilitates neutralization, potentially preventing infection.

Composition of Nanoparticles

The engineered liposomes may incorporate DNA or RNA degrading reagents to enhance their antiviral efficacy. Various enzymes can be included in the formulation, such as DNase or RNase, to degrade viral genetic material. The liposomes are typically unilamellar and range in size from 30 to 500 nm, allowing for effective delivery within the body.

Potential Applications and Administration

The nanoparticles can be administered through various routes including intravenous, intranasal, or oral methods. This flexibility allows for targeted treatment in individuals at risk of viral infections. Additionally, these engineered liposomes may be used in conjunction with other antiviral therapies to improve treatment outcomes against a wide range of enveloped viruses.